The tumor-infiltrating CD8+ T cells were generally amplified with multimodal therapy, notably with the hexatherapy regimen, hexatherapy minus docetaxel, and hexatherapy minus Ad-Twist+N-803 treatments (figure 5D). This evidence concerns the gene CD8A and neoplasm.